scholarly article | Q13442814 |
P50 | author | Nobuo Yaegashi | Q59160672 |
Yoshihito Yokoyama | Q87618863 | ||
Toru Sugiyama | Q88144723 | ||
Yukihiro Terada | Q88518648 | ||
Masayuki Futagami | Q90431145 | ||
Keiya Fujimori | Q92612600 | ||
Tadao Takano | Q114249699 | ||
Hideki Mizunuma | Q114250977 | ||
Toru Tase | Q114560750 | ||
Hirohisa Kurachi | Q114560752 | ||
Takanobu Kojimahara | Q114560780 | ||
P2093 | author name string | Naoki Sato | |
Hiroshi Nishiyama | |||
Jun Watanabe | |||
Fumiharu Miura | |||
P2860 | cites work | Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 |
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin | Q34604181 | ||
Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease | Q34826559 | ||
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials | Q36467605 | ||
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study | Q44315213 | ||
Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer? | Q44927653 | ||
[Second-line treatment using novel chemotherapeutic and biologic agents]. | Q46001580 | ||
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse | Q46082130 | ||
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. | Q53227029 | ||
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. | Q53300225 | ||
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds | Q68927282 | ||
Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation | Q83859008 | ||
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial | Q84574337 | ||
P433 | issue | 2 | |
P921 | main subject | ovarian cancer | Q172341 |
P304 | page(s) | 212-218 | |
P577 | publication date | 2013-12-10 | |
P1433 | published in | Molecular and Clinical Oncology | Q27725125 |
P1476 | title | Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer | |
P478 | volume | 2 |
Q47586504 | Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system (Review). |
Q40768444 | Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer |
Q38818448 | Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models |
Q34631089 | The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer |
Search more.